KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Current Assets (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Current Assets for 8 consecutive years, with $361.1 million as the latest value for Q4 2025.

  • Quarterly Current Assets changed 0.26% to $361.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $361.1 million through Dec 2025, changed 0.26% year-over-year, with the annual reading at $361.1 million for FY2025, 0.26% changed from the prior year.
  • Current Assets hit $361.1 million in Q4 2025 for Castle Biosciences, up from $357.6 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $426.7 million in Q1 2021 to a low of $269.1 million in Q2 2023.
  • Historically, Current Assets has averaged $332.4 million across 5 years, with a median of $340.6 million in 2022.
  • Biggest five-year swings in Current Assets: surged 266.08% in 2021 and later dropped 23.15% in 2022.
  • Year by year, Current Assets stood at $353.7 million in 2021, then decreased by 17.37% to $292.3 million in 2022, then rose by 1.15% to $295.6 million in 2023, then grew by 21.82% to $360.2 million in 2024, then rose by 0.26% to $361.1 million in 2025.
  • Business Quant data shows Current Assets for CSTL at $361.1 million in Q4 2025, $357.6 million in Q3 2025, and $348.7 million in Q2 2025.